INGN

NASDAQ

Inogen Inc

SectorHealth CareIndustryIndustrial SpecialtiesIPO2014

News25/Ratings11

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

News · 26 weeks31+25%

2025-10-262026-04-19

Mix2390d

Insider8(35%)
SEC Filings6(26%)
Other5(22%)
Earnings2(9%)
Leadership2(9%)

Latest news

25 items

16hPR
Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2026 financial results after the market closes on Thursday, May 7, 2026. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: U.S. domestic callers (877) 841-3961 Non-U.S. callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I
6dSEC
SEC Form PRE 14A filed by Inogen Inc
PRE 14A - Inogen Inc (0001294133) (Filer)
15dINSIDER
SEC Form 4 filed by Richardson Jason Andrew
4 - Inogen Inc (0001294133) (Issuer)
15dINSIDER
SEC Form 3 filed by new insider Richardson Jason Andrew
3 - Inogen Inc (0001294133) (Issuer)
17dSEC
Inogen Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Inogen Inc (0001294133) (Filer)
17dPR
Inogen Announces the Appointment of Vafa Jamali to Board of Directors
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Vafa Jamali as an independent director to the Inogen Board of Directors (the "Board"), effective on the date of the Company's 2026 Annual Meeting, or June 15th if earlier. Mr. Jamali is a long-time medical device executive who will bring added depth and expertise to the Board. During his tenure as the Chief Executive Officer of ZimVie, he led the company's Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support
23dPR
Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that Kevin Smith, President and Chief Executive Officer, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 10:15 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-publi
24dSEC
Inogen Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Inogen Inc (0001294133) (Filer)
24dPR
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Compensation Committee of Inogen's Board of Directors approved awards of restricted stock units as material inducement to Jason Richardson and Dominic Hulton entering into employment with the company to serve as its Chief Financial Officer and Chief Marketing Officer, respectively. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with Inogen
24dPR
Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth
Jason Richardson Named Chief Financial Officer, Succeeding Michael Bourque Dominic Hulton Named Chief Marketing Officer Corey Moritz Appointed Vice President, U.S. Business to Business Sales Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the following leadership appointments designed to accelerate the company's next phase of growth. Jason Richardson Appointed Chief Financial Officer Jason Richardson has been appointed Chief Financial Officer, effective April 6, 2026. Mr. Richardson succeeds Michael Bourque, who will step down from his role as Chief Financial Officer on that date. M
27dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Inogen Inc
SCHEDULE 13G/A - Inogen Inc (0001294133) (Subject)
49dPR
Inogen Announces Participation in the KeyBanc Virtual Life Sciences & MedTech Investor Forum
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that Kevin Smith, President and Chief Executive Officer, will participate in a virtual fireside chat at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 17, 2026 at 3:00 p.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-p
51dINSIDER
VP, Chief Accounting Officer Wright Mary E was granted 2,851 shares, converted options into 7,506 shares and covered exercise/tax liability with 3,408 shares, increasing direct ownership by 57% to 19,129 units (SEC Form 4)
4 - Inogen Inc (0001294133) (Issuer)
51dINSIDER
EVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M converted options into 25,017 shares, covered exercise/tax liability with 15,382 shares and was granted 3,603 shares, increasing direct ownership by 98% to 26,747 units (SEC Form 4)
4 - Inogen Inc (0001294133) (Issuer)
51dINSIDER
EVP, Bus Dev, GC & Sec Smith Kevin P. converted options into 14,005 shares, covered exercise/tax liability with 6,276 shares and was granted 1,500 shares, increasing direct ownership by 72% to 22,007 units (SEC Form 4)
4 - Inogen Inc (0001294133) (Issuer)
51dINSIDER
Chief Commercial Officer Ramade Gregoire converted options into 13,005 shares and covered exercise/tax liability with 6,022 shares, increasing direct ownership by 19% to 44,229 units (SEC Form 4)
4 - Inogen Inc (0001294133) (Issuer)
51dINSIDER
CEO and President Smith Kevin Raymond Merrill was granted 33,410 shares, covered exercise/tax liability with 44,585 shares and converted options into 58,346 shares, increasing direct ownership by 55% to 133,462 units (SEC Form 4)
4 - Inogen Inc (0001294133) (Issuer)
51dINSIDER
EVP, CFO & Treasurer Bourque Michael J. was granted 29,749 shares, converted options into 42,007 shares and covered exercise/tax liability with 26,306 shares, increasing direct ownership by 92% to 94,596 units (SEC Form 4)
4 - Inogen Inc (0001294133) (Issuer)
55dSEC
SEC Form S-8 filed by Inogen Inc
S-8 - Inogen Inc (0001294133) (Filer)
55dSEC
SEC Form 10-K filed by Inogen Inc
10-K - Inogen Inc (0001294133) (Filer)
58dSEC
Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Inogen Inc (0001294133) (Filer)
58dPR
Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook
Delivered full year revenue growth of approximately 4% Significantly improved profitability with 2025 net loss of $22.7 million and positive adjusted EBITDA of $2.7 million Well-positioned to accelerate expected 2026 revenue growth and profitability Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year. "In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundam
58dPR
Inogen Announces $30 Million Share Repurchase Program
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has authorized a share repurchase program for up to $30 million of its outstanding common stock. "This authorization reflects our confidence in Inogen's strategy, progress towards profitability goals, and long-term growth trajectory," said Kevin Smith, President and Chief Executive Officer. "With a strong, debt-free balance sheet, we view this program as providing additional flexibility to deploy capital to support continued investment in innovation and portfolio expansion while enhancing shareholder value." The r
101dSEC
Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Inogen Inc (0001294133) (Filer)
101dPR
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025
Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced preliminary, unaudited revenue results for the quarter and year ended December 31, 2025. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2025 to be approximately $82 million, representing year-over-year growth of approximately 2%. Full year 2025 total preliminary, unaudited revenue is expected to be approximately $349 million, representing year-over-year growth of approximately 4%. For the full year 2025, the Com